286 related articles for article (PubMed ID: 7740505)
1. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
[TBL] [Abstract][Full Text] [Related]
2. Hemostasis, platelet function and serotonin in acute and chronic renal failure.
Malyszko J; Malyszko JS; Pawlak D; Pawlak K; Buczko W; Mysliwiec M
Thromb Res; 1996 Sep; 83(5):351-61. PubMed ID: 8873344
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.
Borawski J; Rydzewski A; Pawlak K; Azzadin A; Buczko W; Mysliwiec M
Thromb Res; 1998 May; 90(4):171-80. PubMed ID: 9692616
[TBL] [Abstract][Full Text] [Related]
4. Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients.
Malyszko J; Mazerska M; Malyszko J; Pawlak K; Azzadin A; Mysliwiec M; Buczko W
Int J Clin Lab Res; 1993; 23(1):42-4. PubMed ID: 8477092
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and uremic platelet aggregation in vivo and in vitro.
Malyszko JS; Malyszko J; Pawlak K; Mysliwiec M
Int J Clin Lab Res; 1996; 26(3):199-202. PubMed ID: 8905452
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M
Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin.
Zirkman DM; Zeigler ZR; Fraley DS; Bruns FJ; Adler S
Am J Kidney Dis; 1993 Jan; 21(1):31-7. PubMed ID: 8418623
[TBL] [Abstract][Full Text] [Related]
8. The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure.
Stenver D; Jeppesen L; Nielsen B; Dalsgaard Nielsen J; Haedersdal C; Mehlsen J; Winther K
Int J Artif Organs; 1994 Mar; 17(3):141-5. PubMed ID: 8050804
[TBL] [Abstract][Full Text] [Related]
9. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive study on platelet function, hemostasis, fibrinolysis, peripheral serotonergic system and serum lipids in nephrotic syndrome.
Małyszko J; Małyszko JS; Pawlak D; Pawlak K; Rydzewski A; Myśliwiec M; Buczko W
Pol J Pharmacol; 1996; 48(2):191-5. PubMed ID: 9112650
[TBL] [Abstract][Full Text] [Related]
11. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
[TBL] [Abstract][Full Text] [Related]
12. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
[TBL] [Abstract][Full Text] [Related]
13. Ketanserin lowers erythropoietin concentration in hemodialyzed patients treated with the hormone.
Borawski J; Mazerska M; Pawlak K; Mysliwiec M
J Cardiovasc Pharmacol; 1995 Oct; 26(4):621-6. PubMed ID: 8569225
[TBL] [Abstract][Full Text] [Related]
14. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: association with early improvement in platelet function.
Tàssies D; Reverter JC; Cases A; Calls J; Escolar G; Ordinas A
Am J Hematol; 1998 Oct; 59(2):105-9. PubMed ID: 9766793
[TBL] [Abstract][Full Text] [Related]
15. [Erythropoietin and fibrinolysis in uremic patients].
Małyszko J; Pawlak K; Mazerska M; Małyszko J; Myśliwiec M
Pol Arch Med Wewn; 1993 Oct; 90(4):267-9. PubMed ID: 8127792
[TBL] [Abstract][Full Text] [Related]
16. Some aspects of hemostasis in CAPD patients treated with erythropoietin.
Małyszko J; Suchowierska E; Małyszko JS; Myśliwiec M
Kidney Blood Press Res; 2002; 25(4):240-4. PubMed ID: 12424426
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin treatment improves platelet function in uremic patients.
Cases A; Escolar G; Reverter JC; Ordinas A; Lopez-Pedret J; Revert L; Castillo R
Kidney Int; 1992 Sep; 42(3):668-72. PubMed ID: 1405344
[TBL] [Abstract][Full Text] [Related]
18. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
[TBL] [Abstract][Full Text] [Related]
19. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin.
Małyszko JS; Małyszko J; Pawlak K; Pawlak D; Buczko W; Myśliwiec M
Nephron; 2000 Apr; 84(4):305-11. PubMed ID: 10754406
[TBL] [Abstract][Full Text] [Related]
20. The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients.
Wirtz JJ; van Esser JW; Hamulyák K; Leunissen KM; van Hooff JP
Clin Nephrol; 1992 Nov; 38(5):277-82. PubMed ID: 1451341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
